The antihypertensive effect of arginine

International Journal of Angiology

Volumn 17, Issue 1, 2008, Pages 7-22

  Vasdev, Sudesh ^a   Gill, Vicki ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Advanced glycation end products; Arginine; Hypertension; Insulin resistance; Nitric oxide; Oxidative stress; Renin angiotensin system

Indexed keywords

EID: 80052991138     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1278274     Document Type: Review

References (219)

1. World Health Organization. Global strategy on diet, physical activity, and health: Chronic disease risk factors. www.who.int/dietphysicalactivity/ publications/facts/riskfactors/en (Version current at November 28, 2007).
2. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7. (Pubitemid 17118813)
3. Reaven GM. Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med 1991;90:7S-12S.
4. Sagar S, Kallo IJ, Kaul N, Ganguly NK, Sharma BK. Oxygen free radicals in essential hypertension. Mol Cell Biochem 1992;111:103-8.
5. Kumar K V, Das UN. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res Commun 1993;19:59-66. (Pubitemid 23310628)
6. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993;87:1475-81. (Pubitemid 23133090)
7. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998;97:2222-9. (Pubitemid 28265383)
8. Hill GS, Heudes D, Jacquot C, Gauthier E, Bariety J. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int 2006;69:823-31.
9. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986;8:II127-34. (Pubitemid 16035851)
10. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336:1117-24.
11. Sacks FM, Svetkey LP, Vollmer WM, et al; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10. (Pubitemid 32064838)
12. Elliott P. Protein intake and blood pressure in cardiovascular disease. Proc Nutr Soc 2003;62:495-504.
13. Appel LJ, Sacks FM, Carey VJ, et al. OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: Results of the OmniHeart randomized trial. JAMA 2005;294:2455-64. (Pubitemid 41627923)
14. Stamler J, Caggiula A, Grandits GA, Kjelsberg M, Cutler JA. Relationship to blood pressure of combinations of dietary macronutrients. Findings of the Multiple Risk Factor Intervention Trial (MRFIT). Circulation 1996;94:2417-23. (Pubitemid 26403567)
15. Stamler J, Elliott P, Kesteloot H, et al. Inverse relation of dietary protein markers with blood pressure. Findings for 10,020 men and women in the INTERSALT study. INTERSALT Cooperative Research Group. INTERnational study of SALT and blood pressure. Circulation 1996;94:1629-34. (Pubitemid 26320268)
16. Vasdev S, Gill V. Effect of soybean in diet on blood pressure. Hypertens Canada 2006;88:3-5.
17. Patel A, Layne S, Watts D, Kirchner KA. L-arginine administration normalizes pressure natriuresis in hypertensive Dahl rats. Hypertension 1993;22:863-9. (Pubitemid 23358094)
18. Chen PY, Sanders PW. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991;88:1559-67.
19. Chen PY, St John PL, Kirk KA, Abrahamson DR, Sanders PW. Hypertensive nephrosclerosis in the Dahl/Rapp rat. Initial sites of injury and effect of dietary L-arginine supplementation. Lab Invest 1993;68:174-84. (Pubitemid 23084290)
20. He H, Kimura S, Fujisawa Y, et al. Dietary L-arginine supplementation normalizes regional blood flow in Dahl-Iwai salt-sensitive rats. Am J Hypertens 1997;10:89S-93S. (Pubitemid 27239838)
21. Miyata N, Zou A P, Mattson DL, Cowley AW Jr. Renal medullary interstitial infusion of L-arginine prevents hypertension in Dahl salt-sensitive rats. Am J Physiol 1998;275:R1667-73.
22. Zhou MS, Kosaka H, Tian RX, et al. L-arginine improves endothelial function in renal artery of hypertensive Dahl rats. J Hypertens 2001;19:421-9. (Pubitemid 32195378)
23. Fujii S, Zhang L, Igarashi J, Kosaka H. L-arginine reverses p47phox and gp91phox expression induced by high salt in Dahl rats. Hypertension 2003;42:1014-20. (Pubitemid 37413746)
24. Ozcelikay AT, Tay A, Guner S, et al. Reversal effects of L-arginine treatment on blood pressure and vascular responsiveness of streptozotocin- diabetic rats. Pharmacol Res 2000;41:201-9. (Pubitemid 30670336)
25. Tay A, Ozcelikay AT, Altan VM. Effects of L-arginine on blood pressure and metabolic changes in fructose-hypertensive rats. Am J Hypertens 2002;15:72-7. (Pubitemid 34102276)
26. Pezza V, Bernardini F, Pezza E, Pezza B, Curione M. Study of supplemental oral l-arginine in hypertensives treated with enalapril + hydrochlorothiazide. Am J Hypertens 1998;11:1267-70.
27. Campese VM, Amar M, Anjali C, Medhat T, Wurgaft A. Effect of L-arginine on systemic and renal haemodynamics in salt-sensitive patients with essential hypertension. J Hum Hypertens 1997;11:527-32. (Pubitemid 27434782)
28. Vasdev S, Ford CA, Longerich L, Parai S, Gadag V. Aldehyde induced hypertension in rats: Prevention by N-acetylcysteine. Artery 1998;23:10-36. (Pubitemid 30045665)
29. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens 2000;18:567-73. (Pubitemid 30303487)
30. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary lipoic acid supplementation prevents fructose-induced hypertension in rats. Nutr Metab Cardiovasc Dis 2000;10:339-46.
31. Vasdev S, Gill V, Longerich L, Parai S, Gadag V. Salt-induced hypertension in WKY rats: Prevention by alpha-lipoic acid supplementation. Mol Cell Biochem 2003;254:319-26. (Pubitemid 37483768)
32. Vasdev S, Gill V, Singal P. Role of advanced glycation end products in hypertension and atherosclerosis: Therapeutic implications. Cell Biochem Biophys 2007;49:48-63. (Pubitemid 47415346)
33. Wu L. Is methylglyoxal a causative factor for hypertension development? Can J Physiol Pharmacol 2006;84:129-39. (Pubitemid 44011957)
34. Midaoui AE, Elimadi A, Wu L, Haddad PS, de Champlain J. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens 2003;16:173-9. (Pubitemid 36293060)
35. Wang X, Desai K, Chang T, Wu L. Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 2005;23:1565-73. (Pubitemid 41104829)
36. Wang X, Desai K, Clausen JT, Wu L. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 2004;66:2315-21. (Pubitemid 41115295)
37. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener E P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997;100:2158-69. (Pubitemid 27500137)
38. Schulman IH, Zhou MS, Raij L. Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. Curr Hypertens Rep 2005;7:61-7. (Pubitemid 40277791)
39. Schmieder RE, Langenfeld MR, Friedrich A, Schobel H P, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996;94:1304-9. (Pubitemid 26307257)
40. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002;40:872-9. (Pubitemid 35434909)
41. Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006;103:17985-90. (Pubitemid 44852272)
42. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994;94:2511-5. (Pubitemid 24379629)
43. Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol 2002;16:1931-42. (Pubitemid 34828099)
44. Kamide K, Rakugi H, Nagai M, et al. Insulin-mediated regulation of the endothelial renin-angiotensin system and vascular cell growth. J Hypertens 2004;22:121-7. (Pubitemid 38293539)
45. Folli F, Saad MJ, Velloso L, et al. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999;107:133-9. (Pubitemid 29179280)
46. Tiwari S, Riazi S, Ecelbarger CA. Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol 2007;293:F974-84. (Pubitemid 47583930)
47. Sobrevia L, Nadal A, Yudilevich DL, Mann GE. Activation of L-arginine transport (system y+) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. J Physiol 1996;490:775-81.
48. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 2003;83:183-252. (Pubitemid 36459881)
49. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
50. Levy J, Zemel MB, Sowers JR. Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension. Am J Med 1989;87:7S-16S. (Pubitemid 20013341)
51. Beatty OL, Harper R, Sheridan B, Atkinson AB, Bell PM. Insulin resistance in offspring of hypertensive parents. BMJ 1993;307:92-6. (Pubitemid 23189568)
52. Makris TA, Paizis I, Krespi PG, et al. Insulin receptor number is reduced in healthy offspring of patients with essential hypertension. Am J Hypertens 2004;17:911-4. (Pubitemid 39366017)
53. Sanchez-Margalet V, Valle M, Lobon JA, et al. Diminished insulin receptors on erythrocyte ghosts in nonobese patients with essential hypertension independent of hyperinsulinemia. J Cardiovasc Pharmacol 1994;24:74-7. (Pubitemid 24189603)
54. Giner V, Coca A, de la Sierra A. Increased insulin resistance in salt sensitive essential hypertension. J Hum Hypertens 2001;15:481-5. (Pubitemid 32640264)
55. Fuenmayor N, Moreira E, Cubeddu LX. Salt sensitivity is associated with insulin resistance in essential hypertension. Am J Hypertens 1998;11:397-402. (Pubitemid 28231450)
56. Sharma AM, Schorr U, Distler A. Insulin resistance in young salt-sensitive normotensive subjects. Hypertension 1993;21:273-9. (Pubitemid 23065164)
57. Hulman S, Falkner B, Freyvogel N. Insulin resistance in the conscious spontaneously hypertensive rat: Euglycemic hyperinsulinemic clamp study. Metabolism 1993;42:14-8. (Pubitemid 23019926)
58. Mondon CE, Reaven GM, Azhar S, Lee CM, Rabkin R. Abnormal insulin metabolism by specific organs from rats with spontaneous hypertension. Am J Physiol 1989;257:E491-8.
59. Lembo G, Iaccarino G, Vecchione C, Rendina V, Trimarco B. Insulin modulation of vascular reactivity is already impaired in prehypertensive spontaneously hypertensive rats. Hypertension 1995;26:290-3.
60. Kahn CR, Saad MJ. Alterations in insulin receptor and substrate phosphorylation in hypertensive rats. J Am Soc Nephrol 1992;3:S69-77.
61. Sechi LA, Griffin CA, Giacchetti G, et al. Abnormalities of insulin receptors in spontaneously hypertensive rats. Hypertension 1996;27:955-61. (Pubitemid 26113844)
62. Zecchin HG, Bezerra RM, Carvalheira JB, et al. Insulin signalling pathways in aorta and muscle from two animal models of insulin resistance-the obese middle-aged and the spontaneously hypertensive rats. Diabetologia 2003;46:479-91. (Pubitemid 36577790)
63. Donovan DS, Solomon CG, Seely EW, Williams GH, Simonson DC. Effect of sodium intake on insulin sensitivity. Am J Physiol 1993;264:E730-4. (Pubitemid 23156746)
64. Ogihara T, Asano T, Ando K, et al. High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats. Hypertension 2002;40:83-9. (Pubitemid 34755984)
65. Sechi LA, Griffin CA, Zingaro L, et al. Glucose metabolism and insulin receptor binding and mRNA levels in tissues of Dahl hypertensive rats. Am J Hypertens 1997;10:1223-30. (Pubitemid 28005344)
66. Ogihara T, Asano T, Ando K, et al. Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats. Diabetes 2001;50:573-83. (Pubitemid 32195222)
67. Sechi LA, Griffin CA, Schambelan M. Effect of dietary sodium chloride on insulin receptor number and mRNA levels in rat kidney. Am J Physiol 1994;266:F31-8.
68. Cowley AW Jr, Mori T, Mattson D, Zou AP. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 2003;284:R1355-69. (Pubitemid 36621413)
69. Taddei S, Ghiadoni L, Virdis A, Versari D, Salvetti A. Mechanisms of endothelial dysfunction: Clinical significance and preventive non-pharmacological therapeutic strategies. Curr Pharm Des 2003;9:2385-402. (Pubitemid 37236360)
70. Kahn NN, Acharya K, Bhattacharya S, et al. Nitric oxide: The "second messenger" of insulin. IUBMB Life 2000;49:441-50. (Pubitemid 30436180)
71. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539-45. (Pubitemid 30180890)
72. Moss MB, Brunini TM, Soares De Moura R, et al. Diminished L-arginine bioavailability in hypertension. Clin Sci (Lond) 2004;107:391-7. (Pubitemid 39389306)
73. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997;1:65-73. (Pubitemid 28078129)
74. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004;24:413-20. (Pubitemid 38326132)
75. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc Natl Acad Sci USA 1998;95:9220-5. (Pubitemid 28506212)
76. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111:1201-9. (Pubitemid 36519937)
77. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Diez J. Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction? Nephrol Dial Transplant 2001;16 Suppl 1:2-5. (Pubitemid 32492496)
78. 2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998;273:25804-8.
79. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-4.
80. Bragulat E, de la Sierra A, Antonio MT, Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension 2001;37:444-8. (Pubitemid 32199009)
81. Higashi Y, Sasaki S, Nakagawa K, Fukuda et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 2002;15:326-32. (Pubitemid 34408972)
82. Li H, Witte K, August M, Brausch I, et al. Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol 2006;47:2536-44. (Pubitemid 43866358)
83. Newaz MA, Nawal NN, Rohaizan CH, Muslim N, Gapor A. Alpha-tocopherol increased nitric oxide synthase activity in blood vessels of spontaneously hypertensive rats. Am J Hypertens 1999;12:839-44. (Pubitemid 29416802)
84. Cubeddu LX, Alfieri AB, Hoffmann IS, et al. Nitric oxide and salt sensitivity. Am J Hypertens 2000;13:973-9.
85. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: Modulation of nitric oxide synthesis by salt intake. Circulation 2000;101:856-61. (Pubitemid 30117880)
86. Bayorh MA, Ganafa AA, Socci RR, Silvestrov N, Abukhalaf IK. The role of oxidative stress in salt-induced hypertension. Am J Hypertens 2004;17:31-6. (Pubitemid 38064756)
87. Hu L, Manning RD Jr. Role of nitric oxide in regulation of long-term pressure-natriuresis relationship in dahl rats. Am J Physiol 1995;268:H2375-83.
88. Johnson RJ, Gordon KL, Giachelli C, Kurth T, Skelton MM, Cowley AW Jr. Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat. J Hypertens 2000;18:1497-505.
89. Ni Z, Oveisi F, Vaziri ND. Nitric oxide synthase isotype expression in salt-sensitive and salt-resistant Dahl rats. Hypertension 1999;34:552-7. (Pubitemid 29496432)
90. Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-97. (Pubitemid 46127306)
91. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8. (Pubitemid 24176909)
92. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-51. (Pubitemid 30151676)
93. Wolf G, Jablonski K, Schroeder R, Reinking R, Shankland SJ, Stahl RA. Angiotensin II-induced hypertrophy of proximal tubular cells requires p27Kip1. Kidney Int 2003;64:71-81. (Pubitemid 36714159)
94. Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: A lesson from clinical trials. Curr Pharm Des 2007;13:1335-45. (Pubitemid 46746371)
95. Delles C, Schneider M P, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002;15:590-3. (Pubitemid 34734805)
96. Kobori H, Nishiyama A, Abe Y, Navar LG. Enhancement of intrarenal angiotensinogen in dahl salt-sensitive rats on high salt diet. Hypertension 2003;41:592-597. (Pubitemid 36314637)
97. Strehlow K, Nickenig G, Roeling J, et al. AT(1) receptor regulation in salt-sensitive hypertension. Am J Physiol 1999;277:H1701-7.
98. Chandramohan G, Bai Y, Norris K, Rodriguez-Iturbe B, Vaziri ND. Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-kappaB activity in salt-sensitive and-resistant rat kidneys. Am J Nephrol 2008;28:158-67. (Pubitemid 350126507)
99. Luvara G, Pueyo ME, Philippe M, et al. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: Prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 1998;18:1408-16. (Pubitemid 28421878)
100. Ikemoto F, Song G, Tominaga M, Yamamoto K. Oxidation-induced increase in activity of angiotensin converting enzyme in the rat kidney. Biochem Biophys Res Commun 1988;153:1032-7.
101. Tuck ML, Bounoua F, Eslami P, Nyby MD, Eggena P, Corry DB. Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J Hypertens 2004;22:1779-85. (Pubitemid 39141971)
102. Thomas MC, Tikellis C, Burns WM, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;16:2976-84. (Pubitemid 44743495)
103. Andreozzi F, Laratta E, Sciacqua A, Perticone F, Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 2004;94:1211-8. (Pubitemid 38656407)
104. Horiuchi M, Mogi M, Iwai M. Signaling crosstalk angiotensin II receptor subtypes and insulin. Endocr J 2006;53:1-5.
105. Beisswenger PJ, Makita Z, Curphey TJ, et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995;44:824-9.
106. Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000;37:87-92. (Pubitemid 32009315)
107. Meerwaldt R, Links TP, Graaff R, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005;48:1637-44. (Pubitemid 41175518)
108. Mostafa AA, Randell EW, Vasdev SC, et al. Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol Cell Biochem 2007;302:35-42. (Pubitemid 47202318)
109. Wang X, Chang T, Jiang B, Desai K, Wu L. Attenuation of hypertension development by aminoguanidine in spontaneously hypertensive rats: Role of methylglyoxal. Am J Hypertens 2007;20:629-36. (Pubitemid 46777256)
110. Thornalley PJ. The glyoxalase system in health and disease. Mol Aspects Med 1993;14:287-371.
111. Beisswenger PJ, Howell SK, Smith K, Szwergold BS. Glyceraldehyde-3- phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim Biophys Acta 2003;1637:98-106. (Pubitemid 36071602)
112. O'Brien PJ, Siraki AG, Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 2005;35:609-62. (Pubitemid 41693601)
113. Zeng J, Davies MJ. Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem Res Toxicol 2005;18:1232-41. (Pubitemid 41170247)
114. Thornalley PJ, Battah S, Ahmed N, et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003;375:581-92. (Pubitemid 37433506)
115. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids 2003;25:275-81. (Pubitemid 38041265)
116. Morgan PE, Dean RT, Davies MJ. Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products. Arch Biochem Biophys 2002;403:259-69. (Pubitemid 34800207)
117. Park YS, Koh YH, Takahashi M, Miyamoto Y, et al. Identification of the binding site of methylglyoxal on glutathione peroxidase: Methylglyoxal inhibits glutathione peroxidase activity via binding to glutathione binding sites arg 184 and 185. Free Radic Res 2003;37:205-11. (Pubitemid 36124347)
118. Riboulet-Chavey A, Pierron A, Durand I, Murdaca J, Giudicelli J, Van Obberghen E. Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 2006;55:1289-99. (Pubitemid 44195367)
119. Jia X, Olson DJ, Ross AR, Wu L. Structural and functional changes in human insulin induced by methylglyoxal. FASEB J 2006;20:1555-7.
120. Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003;17:1289-91.
121. Collison KS, Parhar RS, Saleh SS, et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002;71:433-44.
122. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003;25:283-92. (Pubitemid 38041266)
123. Schauenstein E, Esterbauer H, Zollner H. Aldehydes in biological systems. Lagnado JR, Ed. In: Aldehydes in Biological Systems, their Natural Occurrence and Biological Activities. London: Pion Limited, 1977:1-7.
124. 2+ release from sarcoplasmic reticulum via an oxidation reaction. J Biol Chem 1989;264:21725-36. (Pubitemid 20028742)
125. Aoki K, Kawaguchi Y, Sato K, Kondo S, Yamamoto M. Clinical and pharmacological properties of calcium antagonists in essential hypertensionin humans and spontaneously hypertensive rats. J Cardiovasc Pharmacol 1982;4:S298-S302. (Pubitemid 13173972)
126. Robinson BF. Altered caclium handling as a cause of primary hypertension. J Hypertens 1984;2:435-60.
127. Stadtman TC. Selenium biochemistry. Annu Rev Biochem 1990;59:111-27.
128. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685-94.
129. Wu L, Juurlink BH. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 2002;39:809-14. (Pubitemid 34252881)
130. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 2000;278:F676-83. (Pubitemid 30215247)
131. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: Implications in hypertension. Histochem Cell Biol 2004;122:339-52. (Pubitemid 39506592)
132. Brandwein HJ, Lewicki JA, Murad F. Reversible inactivation of guanylate cyclase by mixed disulfide formation. J Biol Chem 1981;256:2958-62. (Pubitemid 11067293)
133. Selwood T, Thornalley PJ. Binding of methylglyoxal to albumin and formation of fluorescent adducts. inhibition by arginine, N-alpha-acetylarginine and aminoguanidine. Biochem Soc Trans 1993;21:170S. (Pubitemid 23167838)
134. Fukami K, Ueda S, Yamagishi S, Kato S, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004;66:2137-47. (Pubitemid 41115277)
135. Bohlender J, Franke S, Sommer M, Stein G. Advanced glycation end products: A possible link to angiotensin in an animal model. Ann N Y Acad Sci 2005;1043:681-4. (Pubitemid 41123960)
136. Tabatabaie T, Floyd RA. Susceptibility of glutathione peroxidase and glutathione reductase to oxidative damage and the protective effect of spin trapping agents. Arch Biochem Biophys 1994;314:112-9. (Pubitemid 24326720)
137. Tsuchiya Y, Yamaguchi M, Chikuma T, Hojo H. Degradation of glyceraldehyde-3-phosphate dehydrogenase triggered by 4-hydroxy-2-nonenal and 4-hydroxy-2-hexenal. Arch Biochem Biophys 2005;438:217-22. (Pubitemid 40798021)
138. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 2003;30:860-6. (Pubitemid 37506154)
139. Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci 2003;28:509-14. (Pubitemid 38340416)
140. Tabet F, Savoia C, Schiffrin EL, Touyz RM. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004;44:200-8. (Pubitemid 38982163)
141. 2-induced vascular relaxation by endothelium-derived relaxing factor. Mol Cell Biochem 1995;149-150:267-70.
142. Bharadwaj L, Prasad K. Mechanism of superoxide anion-induced modulation of vascular tone. Int J Angiol 200211;23-9.
143. Prabha PS, Das UN, Koratkar R, Sagar PS, Ramesh G. Free radical generation, lipid peroxidation and essential fatty acids in uncontrolled essential hypertension. Prostaglandins Leukot Essent Fatty Acids 1990;41:27-33. (Pubitemid 20284955)
144. Parik T, Allikmets K, Teesalu R, Zilmer M. Evidence for oxidative stress in essential hypertension: Perspective for antioxidant therapy. J Cardiovasc Risk 1996;3:49-54. (Pubitemid 126424946)
145. Tandon R, Sinha MK, Garg H, Khanna R, Khanna HD. Oxidative stress in patients with essential hypertension. Natl Med J India 2005;18:297-9. (Pubitemid 43230597)
146. Biswas SK, de Faria JB. Which comes first: Renal inflammation or oxidative stress in spontaneously hypertensive rats? Free Radic Res 2007;41:216-24. (Pubitemid 46992872)
147. Fortuno A, Olivan S, Beloqui O, et al. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 2004;22:2169-75. (Pubitemid 39463811)
148. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: Role of nitric oxide. Hypertension 1998;32:59-64. (Pubitemid 28324125)
149. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary vitamin C supplementation lowers blood pressure in spontaneously hypertensive rats. Mol Cell Biochem 2001;218:97-103. (Pubitemid 32294140)
150. Vasdev S, Gill V, Parai S, Longerich L, Gadag V. Dietary vitamin E supplementation lowers blood pressure in spontaneously hypertensive rats. Mol Cell Biochem 2002;238:111-7. (Pubitemid 35023534)
151. Vasdev S, Gill V. Antioxidants in the treatment of hypertension. Int J Angiol 2005;14:60-73. (Pubitemid 43183956)
152. Trolliet MR, Rudd MA, Loscalzo J. Oxidative stress and renal dysfunction in salt-sensitive hypertension. Kidney Blood Press Res 2001;24:116-23. (Pubitemid 32642065)
153. Kitiyakara C, Chabrashvili T, Chen Y, et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 2003;14:2775-82. (Pubitemid 37305640)
154. Vasdev S, Gill V, Parai S, Gadag V. Dietary vitamin e supplementation attenuates hypertension in Dahl salt-sensitive rats. J Cardiovasc Pharmacol Ther 2005;10:103-111. (Pubitemid 40847872)
155. Vasdev S, Gill V, Parai S, Gadag V. Dietary lipoic acid supplementation attenuates hypertension in Dahl salt sensitive rats. Mol Cell Biochem 2005;275:135-141. (Pubitemid 41030989)
156. Pennington JAT. Supplementary tables-amino acids. In: Allen A, ed. Bowes & Church's Food Values of Portions Commonly Used, 16th edn. Philadelphia: JB Lippincott Company, 1994:A325-77.
157. Brosnan ME, Brosnan JT. Renal arginine metabolism. J Nutr 2004;134:2791S-5S. (Pubitemid 39315222)
158. Tong BC, Barbul A. Cellular and physiological effects of arginine. Mini Rev Med Chem 2004;4:823-32. (Pubitemid 39200069)
159. Xiao S, Wagner L, Mahaney J, Baylis C. Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am J Physiol Renal Physiol 2001;280:F989-95.
160. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2006;2:209-20. (Pubitemid 43787287)
161. Brunini T, Moss M, Siqueira M, et al. Inhibition of l-arginine transport in platelets by asymmetric dimethylarginine and N-monomethyl-l-arginine: Effects of arterial hypertension. Clin Exp Pharmacol Physiol 2004;31:738-40. (Pubitemid 39540326)
162. Fajans SS, Floyd JC,Jr, Knopf RF, Conn FW. Effect of amino acids and proteins on insulin secretion in man. Recent Prog Horm Res 1967;23:617-62.
163. Sener A, Best LC, Yates A P, et al. Stimulus-secretion coupling of arginine-induced insulin release: Comparison between the cationic amino acid and its methyl ester. Endocrine 2000;13:329-40. (Pubitemid 32108061)
164. Eid HM, Reims H, Arnesen H, Kjeldsen SE, Lyberg T, Seljeflot I. Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism 2007;56:464-9. (Pubitemid 46427842)
165. Higashi Y, Oshima T, Ono N, et al. Intravenous administration of L-arginine inhibits angiotensin-converting enzyme in humans. J Clin Endocrinol Metab 1995;80:2198-202.
166. Lubec B, Hayn M, Kitzmuller E, Vierhapper H, Lubec G. L-arginine reduces lipid peroxidation in patients with diabetes mellitus. Free Radic Biol Med 1997;22:355-7.
167. Wascher TC, Posch K, Wallner S, Hermetter A, Kostner GM, Graier WF. Vascular effects of L-arginine: Anything beyond a substrate for the NO-synthase? Biochem Biophys Res Commun 1997;234:35-8. (Pubitemid 27267526)
168. Higashi Y, Oshima T, Watanabe M, Matsuura H, Kajiyama G. Renal response to L-arginine in salt-sensitive patients with essential hypertension. Hypertension 1996;27:643-8. (Pubitemid 26084632)
169. Murakami K, Kojima S, Kimura G, et al. The association between salt sensitivity of blood pressure and family history of hypertension. Clin Exp Pharmacol Physiol Suppl 1992;20:61-3.
170. Artigues C, Richard V, Roussel C, Lallemand F, Henry JP, Thuillez C. Increased endothelium-monocyte interactions in salt-sensitive hypertension: Effect of L-arginine. J Cardiovasc Pharmacol 2000;35:468-73. (Pubitemid 30127196)
171. Schlaich MP, Parnell MM, Ahlers BA, Finch et al. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation 2004;110:3680-6. (Pubitemid 39665257)
172. Ono H, Ono Y, Frohlich ED. L-arginine reverses severe nephrosclerosis in aged spontaneously hypertensive rats. J Hypertens 1999;17:121-8. (Pubitemid 29086197)
173. Matsuoka H, Nakata M, Kohno K, et al. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 1996;27:14-8. (Pubitemid 26017675)
174. Vukosavljevic N, Jaron D, Barbee KA, Buerk DG. Quantifying the L-arginine paradox in vivo. Microvasc Res 2006;71:48-54. (Pubitemid 43175848)
175. Wood PA, Hamm DA, Chen PY, Sanders PW. Studies of arginine metabolism and salt sensitivity in the Dahl/Rapp rat models of hypertension. Mol Genet Metab 1998;64:80-3. (Pubitemid 28453323)
176. Zhang C, Hein TW, Wang W, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004;44:935-43. (Pubitemid 39577425)
177. Demougeot C, Prigent-Tessier A, Bagnost T, et al. Time course of vascular arginase expression and activity in spontaneously hypertensive rats. Life Sci 2007;80:1128-34. (Pubitemid 46241221)
178. Johnson FK, Johnson RA, Peyton KJ, Durante W. Arginase inhibition restores arteriolar endothelial function in dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2005;288:R1057-62. (Pubitemid 40404183)
179. Milner JA. Metabolic aberrations associated with arginine deficiency. J Nutr 1985;115:516-23. (Pubitemid 15083810)
180. Visek WJ. Arginine needs, physiological state and usual diets. A reevaluation. J Nutr 1986;116:36-46. (Pubitemid 16212053)
181. Wells BJ, Mainous AG,3rd, Everett CJ. Association between dietary arginine and C-reactive protein. Nutrition 2005;21:125-30. (Pubitemid 40255719)
182. Oomen CM, van Erk MJ, Feskens EJ, Kok FJ, Kromhout D. Arginine intake and risk of coronary heart disease mortality in elderly men. Arterioscler Thromb Vasc Biol 2000;20:2134-9.
183. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005;46:518-23. (Pubitemid 41040296)
184. Rytlewski K, Olszanecki R, Korbut R, Zdebski Z. Effects of prolonged oral supplementation with l-arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest 2005;35:32-7. (Pubitemid 40187952)
185. Evans RW, Fernstrom JD, Thompson J, Morris SM Jr, Kuller LH. Biochemical responses of healthy subjects during dietary supplementation with L-arginine. J Nutr Biochem 2004;15:534-9. (Pubitemid 39209396)
186. West SG, Likos-Krick A, Brown P, Mariotti F. Oral L-arginine improves hemodynamic responses to stress and reduces plasma homocysteine in hypercholesterolemic men. J Nutr 2005;135:212-7. (Pubitemid 40194480)
187. Theilmeier G, Chan JR, Zalpour C, et al. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vasc Biol 1997;17:3557-64. (Pubitemid 28028568)
188. Wang J, Sim AS, Wang XL, Wilcken DE. L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells. Cell Mol Life Sci 2006;63:2838-46. (Pubitemid 44913323)
189. Stuhlinger MC, Abbasi F, Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420-6. (Pubitemid 34250505)
190. Cardounel AJ, Cui H, Samouilov A, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007;282:879-887. (Pubitemid 47076535)
191. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455-9. (Pubitemid 36994536)
192. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652-8. (Pubitemid 29164831)
193. Jia SJ, Jiang DJ, Hu C P, Zhang XH, Deng HW, Li YJ. Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells. Vascul Pharmacol 2006;44:143-8.
194. Fang Y, Mu JJ, He LC, Wang SC, Liu ZQ. Salt loading on plasma asymmetrical dimethylarginine and the protective role of potassium supplement in normotensive salt-sensitive asians. Hypertension 2006;48:724-9. (Pubitemid 44843878)
195. Matsuoka H, Itoh S, Kimoto M, et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997;29:242-7. (Pubitemid 27074050)
196. Carter BW,Jr, Chicoine LG, Nelin LD. L-lysine decreases nitric oxide production and increases vascular resistance in lungs isolated from lipopolysaccharide-treated neonatal pigs. Pediatr Res 2004;55:979-87. (Pubitemid 38661790)
197. Yang Z, Kaye DM. Endothelial dysfunction and impaired L-arginine transport in hypertension and genetically predisposed normotensive subjects. Trends Cardiovasc Med 2006;16:118-24.
198. Tomohiro A, Kimura S, He H, et al. Regional blood flow in Dahl-Iwai salt-sensitive rats and the effects of dietary L-arginine supplementation. Am J Physiol 1997;272:R1013-9.
199. De Pirro R, Tamburrano G, Fusco A, Lauro R. Arginine does not influence insulin binding on circulating monocytes. 1980;75:243-6.
200. Wascher TC, Graier WF, Dittrich P, et al. Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity. Eur J Clin Invest 1997;27:690-5. (Pubitemid 27368301)
201. Piatti PM, Monti LD, Valsecchi G, et al. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 2001;24:875-80. (Pubitemid 33636062)
202. Ahmed N, Thornalley PJ. Advanced glycation endproducts: What is their relevance to diabetic complications? Diabetes Obes Metab 2007;9:233-45. (Pubitemid 46502041)
203. Servetncik DA, Bryant D, Wells-knetch KJ, Wiesenfeld PL. L-arginine inhibits in vitro nonenzymatic glycation and advanced glycosylated end product formation of human serum albumin. 1996;11:69-81.
204. Weninger M, Xi Z, Lubec B, Szalay S, Hoger H, Lubec G. L-arginine reduces glomerular basement membrane collagen N epsilon-carboxymethyllysine in the diabetic db/db mouse. Nephron 1992;62:80-3.
205. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002;99:13527-32. (Pubitemid 35215415)
206. Lekakis J P, Papathanassiou S, Papaioannou TG, et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 2002;86:317-23. (Pubitemid 35284824)
207. Hodroj W, Legedz L, Foudi N, et al. Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler Thromb Vasc Biol 2007;27:525-31.
208. Nagase S, Takemura K, Ueda A, Hirayama et al. A novel nonenzymatic pathway for the generation of nitric oxide by the reaction of hydrogen peroxide and D-or L-arginine. Biochem Biophys Res Commun 1997;233:150-3. (Pubitemid 27215926)
209. Majid DS, Kopkan L. Nitric oxide and superoxide interactions in the kidney and their implication in the development of salt-sensitive hypertension. Clin Exp Pharmacol Physiol 2007;34:946-52. (Pubitemid 47083962)
210. Wu G, Bazer FW, Cudd TA, et al. Pharmacokinetics and safety of arginine supplementation in animals. J Nutr 2007;137:1673S-80S. (Pubitemid 46855529)
211. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996;97:1989-94. (Pubitemid 26129888)
212. Wolf A, Zalpour C, Theilmeier G, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997;29:479-85. (Pubitemid 27116086)
213. Chan JR, Boger RH, Bode-Boger SM, et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 2000;20:1040-6. (Pubitemid 30207579)
214. Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang PL. Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice. Arterioscler Thromb Vasc Biol 2003;23:97-103. (Pubitemid 36091632)
215. Loscalzo J. Adverse effects of supplemental L-arginine in atherosclerosis: Consequences of methylation stress in a complex catabolism? Arterioscler Thromb Vasc Biol 2003;23:3-5. (Pubitemid 36091616)
216. -/- double knockout mice. Cell Mol Biol (Noisy-le-grand) 2004;50:903-9.
217. Boger RH, Bode-Boger SM, Brandes R P, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: Comparison with lovastatin. Circulation 1997;96:1282-90. (Pubitemid 27344234)
218. Tsai CH, Pan TL, Lee YS, Tai YK, Liu TZ. Evidence that high-dose L-arginine may be inappropriate for use by diabetic patients as a prophylactic blocker of methylglyoxal glycation. J Biomed Sci 2004;11:692-6.
219. Racasan S, Braam B, van der Giezen DM, et al. Perinatal L-arginine and antioxidant supplements reduce adult blood pressure in spontaneously hypertensive rats. Hypertension 2004;44:83-8. (Pubitemid 38823492)